Gilead Science’s Long-Acting HIV Drug Secures Win With EU Approval

Gilead Science has received approval from the European Commission for its HIV drug lenacapavir. The medication is used to treat multi-drug resistant HIV and is injected once every six months. This approval marks a win for Gilead, as the drug was placed on a temporary clinical by the FDA over the risk of contamination from glass shards.

According to Angus Liu, “The EU approval comes as Gilead plays catch-up with GSK’s ViiV Healthcare in the field of long-acting injectables, which are gaining attention because they offer patients more convenience than daily oral pills. GSK’s Cabenuva is currently available as a full HIV regimen that can be administered once every two months.”

To read more, click here.

(Source: Fierce Pharma, August 22nd, 2022)